Results 161 to 170 of about 2,545,960 (263)

Study on the Chemical Composition and Anti-Tumor Mechanisms of Clausena lansium Fruit By-Products: Based on LC-MS, Network Pharmacology Analysis, and Protein Target Validation. [PDF]

Foods
Zhang Z, Zhang L, Wu P, Tian Y, Wen Y, Xu M, Xu P, Jiang Y, Ma N, Wang Q, Dai W.   +10 more
europepmc   +1 more source

Release of a photopharmacological drug from its protein target captured by time-resolved serial crystallography

, 2022
Wranik M, Weinert T, Slavov C, Masini T, Furrer A, Gaillard N, Gioia D, Ferrarotti M, James D, Glover H, Carrillo M, Kekilli D, Stipp R, Skopintsev P, Brünle S, Mühlethaler T, Beale J, Gashi D, Nass K, Ozerov D, Johnson P, Cirelli C, Bacellar C, Braun M, Wang M, Dworkowski F, Milne C, Cavalli A, Wachtveitl J, Steinmetz M, Standfuss J.   +30 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

PAR-dCLIP: Enabling detection of RNA binding protein target transcripts bound at 5' termini through the incorporation of a decapping step. [PDF]

Methods Enzymol
Lisy S, Rothamel K, Perevalova-Pinzul Y, Ascano M.   +3 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Molecular docking analysis of <i>Salvia sclarea</i> flower extracts evaluated for protein target affinity based on different extraction methods. [PDF]

Food Sci Nutr
Torunoglu EI, Aytar EC, Durmaz A.
europepmc   +1 more source

Comparative Analysis of Mass-Spectrometry-Based Proteomic Methods for Protein Target Discovery Using a One-Pot Approach. [PDF]

J Am Soc Mass Spectrom, 2020
Cabrera A, Wiebelhaus N, Quan B, Ma R, Meng H, Fitzgerald MC.   +5 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Keeping Proteins on Target

PLoS Biology, 2004
openaire   +3 more sources

A simple, robust, broadly applicable insertion mutagenesis method to create random fluorescent protein: target protein fusions. [PDF]

G3 (Bethesda)
Pike A, Pietryski C, Deighan P, Kuehner J, Lau D, Seshan A, March PE.   +6 more
europepmc   +1 more source